NKG2DL expression was repressed by PARP1 recruitment at NKG2DL promoters.
Transplants were performed from 2006-2017 and median follow up is 21 months (range 11-36).
PT-CY was given on Day 3 and Day 5 in group-1 and on day 3 and day 4 in group-2 and 3.
Fifty-eight patients were treated with TKI only (dasatinib, n=50, nilotinib, n=3, ponatinib, n=5), while 82 received additional treatment such as DLI, chemotherapy, or second allo SCT.
Main toxicities of dasatinib were effusion, edema, or other pulmonary complaints (10 - 15% of patients) and infections (13%).
Two-year OS was comparable in patients treated for persisting MRD/MR and for HR (48% and 50%).
Among patients treated with TKI only, 2/5-year OS was 38%/33%.
For treatment, patients received dasatinib (n=104), nilotinib (n=18) and ponatinib (n=18).
Median interval between diagnosis of persisting MRD or MR/HR and first application of a TKI was 10 days, median duration of TKI treatment was 154 days (range 4 - 2193).
Methods: We performed a retrospective, EBMT registry based analysis, including patients with documented use of 2 generation TKI given for persisting MRD, MR or HR after allo SCT in 2006-2016.